An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Daniel S. Mytelka
Advertisement
Articles by Daniel S. Mytelka
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Sends Refusal-to-File Letter to Moderna for Seasonal Influenza Vaccine, Enters Long-Term Agreement with Government of Mexico
2
Today’s China Crucible: What It Means for Pharma
3
FDA Approves Keytruda-Based Regimen for PD-L1–Positive Platinum-Resistant Ovarian Cancer
4
Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
5